Health
Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T - Endpoints News

What the report says
RiboX confirms a patient died in its unregulated China trial for RXIM002, an in vivo CAR-T therapy — the third such disclosed death in recent weeks.
Loading debate for this article…
Other publishers covering this story
No additional verified coverage is currently clustered with this report.

Health Ministry Launches m-PIMA Technology to Expand HIV Testing in Rural AreasNile Post
Akech Warns Health Workers Against Absenteeism as Tetugo HCIII Gets Staff HousesDokolo Post
Ebola disease caused by Bundibugyo virus - Democratic Republic of the CongoWorld Health Organization